The 14th Annual Winter Lung Cancer Conference

February 10-12, 2017, Miami, Florida

The 14th Annual Winter Lung Cancer Conference

Please note that slides are for review only and not to be repurposed or published.


Dr Bunn Jr
History, Major Findings and Lessons from LCMC

SESSION 1: Current and Future Application of Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Module 1.1 — Dr Herbst
Emerging research information with the use of anti-PD-1/PD-L1 antibodies in patients with previously untreated metastatic NSCLC

Module 1.2 — Dr Neal
Practical assessment of PD-L1 status and integration of PD-L1 assays into clinical practice

Module 1.3 — Dr Rizvi
Current role of anti-PD-1/PD-L1 antibodies in patients with EGFR- or ALK-positive disease

Module 1.4 — Dr Pennell
Novel immunotherapeutic approaches; combination strategies with chemotherapy

SESSION 2: EGFR Mutation-Positive NSCLC

Module 2.1 — Dr Bunn
Molecular testing in clinical practice and the role of multiplex testing/next-generation sequencing (NGS)

Module 2.2 — Dr Shaw
Effect of EGFR variant on the selection of first-line systemic therapy

Module 2.3 — Dr Oxnard
Identification of acquired resistance: Detection of T790M and other secondary mutations in tissue, plasma and urine

Module 2.4 — Dr Herbst
Available efficacy and safety data with osimertinib; ongoing evaluation in the first-line setting; effectiveness in patients with CNS metastases

SESSION 3: EML4-ALK, ROS1, BRAF and Other Potentially Targetable Mutations

Module 3.1 — Dr Shaw
Optimal approach to ALK assessment; selection of first-line therapy for patients with ALK-rearranged or ROS1-positive NSCLC

Module 3.2 — Dr Oxnard
Approved and investigational TKIs for patients with ALK-positive disease progressing on first-line TKI therapy

Module 3.3 — Dr Bunn
Identification of and treatment for patients with BRAF-V600E tumor mutations

Module 3.4 — Dr Stinchcombe
Potential clinical benefits of and investigational opportunities associated with the identification of other oncogenic drivers (eg, HER2 and MET exon 14 skipping mutations, RET rearrangements)

SESSION 4: Management of Small Cell Lung Cancer, Mesothelioma and NSCLC with No Identified Targetable Mutations

Module 4.1 — Dr Rizvi
Emerging role of immune checkpoint inhibitors and ongoing clinical trials in malignant pleural mesothelioma (MPM)

Module 4.2 — Dr Stinchcombe
Current management and ongoing clinical trials in small cell lung cancer (SCLC)

Module 4.3 — Dr Socinski
Sequencing of systemic therapies and clinical trial options for patients with metastatic squamous cell carcinoma (SCC)

Module 4.4 — Dr Neal
Sequencing of systemic therapies and clinical trial options for patients with metastatic nonsquamous cell lung cancer

Module 4.5 — Dr Pennell
Is there a role for targeted therapy in the adjuvant or neoadjuvant setting?

SESSION 5: Quality and Value in the Management of Lung Cancer

Module 5.1 — Dr McAneny
The oncology home: Implications for the care of patients with lung cancer

Module 5.2 — Dr Lilenbaum
What clinicians can do about the cost of cancer care

SESSION 6: Lung Cancer Interdisciplinary Tumor Board

Module 6.1 — Dr Vallières
Prognostic molecular models in early-stage lung cancer

Module 6.2 — Dr Decker
Radiation therapy: Challenging clinical scenarios and related management issues

Module 6.3 — Dr Kelly
Adjuvant and neoadjuvant therapy

Module 6.4 — Dr Vallières
Controversies in the surgical management of lung cancer

Module 6.5 — Dr Decker
Recent therapeutic advances and novel trial concepts for patients with locally advanced NSCLC

Module 6.6 — Dr Kris
Optimal management of oligometastatic disease

SESSION 7: Practical Challenges in the Use of Immunotherapy

Module 7.1 — Dr Langer
Clinical complications associated with immunotherapy; immunotherapy in patients with a history of autoimmune disease

Module 7.2 — Dr Kris
Clinically relevant endpoints for checkpoint inhibitor trials; management approach for patients with prolonged progression-free survival: Is there a role for stopping therapy?

Module 7.3 — Dr Kelly
Clinical trials integrating immunotherapy and radiation therapy

Module 7.4 — Dr Langer
Immunotherapy in elderly patients and those with significant comorbidities